GlassScriptPhysician profile
James H Rudick
NPI 1417062928
$1,779.57
in general payments reported to CMS, 2019-2025
26 companies · $173 in 2025
The $173 reported for 2025 was less than what a typical Endocrinology, Diabetes & Metabolism provider received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $279 · 2020: $358 · 2021: $465 · 2022: $287 · 2023: $148 · 2024: $71.25 · 2025: $173.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $391.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $325.39 | 2019-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $219.93 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $163.95 | 2019-2022 | |
| Medtronic, INC. | $120.67 | 2021-2025 | Minimed 780g |
| Amryt Pharma Holdings LTD | $106.47 | 2020-2023 | Mycapssa |
| Corcept Therapeutics | $97.58 | 2019-2021 | |
| Amarin Pharma, INC. | $97.29 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $82.20 | 2021-2025 | Unithroid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.14 | 2019-2022 | |
| Clarus Therapeutics INC. | $55.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.11 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.49 | 2021-2022 | |
| Amgen INC. | $35.69 | 2021-2022 | |
| Ibsa Pharma INC. | $34.97 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $34.78 | 2020-2021 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $32.01 | 2022-2023 | |
| Dexcom, INC. | $31.73 | 2022-2023 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $30.32 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $27.23 | 2019 | |
| Janssen Pharmaceuticals, INC | $25.39 | 2019-2020 | |
| Abbott Laboratories | $24.85 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $21.28 | 2021 | |
| Antares Pharma, INC. | $19.40 | 2020 | |
| Eisai INC. | $15.69 | 2019 | |
| Sequel Med Tech, LLC | $14.82 | 2025 | Twiist |
| Xeris Pharmaceuticals, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Rudick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.